Leveraging Signaling Pathways to Treat Heart Failure With Reduced Ejection Fraction.

ABSTRACT: Advances in the treatment of heart failure with reduced ejection fraction due to systolic dysfunction are engaging an ever-expanding compendium of molecular signaling targets. Well established approaches modifying hemodynamics and cell biology by neurohumoral receptor blockade are evolving, exploring the role and impact of modulating intracellular signaling pathways with more direct myocardial effects. Even well-tread avenues are being reconsidered with new insights into the signaling engaged and thus opportunity to treat underlying myocardial disease. This review explores therapies that have proven successful, those that have not, those that are moving into the clinic but whose utility remains to be confirmed, and those that remain in the experimental realm. The emphasis is on signaling p

SUBMITTER: Pinilla-Vera M 

PROVIDER: S-EPMC6534150 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature